Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Why quote that little section when it says what the 4 projects are?
Here it is: HERE

The funded projects are:
• A Phase II clinical trial of the FDA-approved drug Leukine, to determine whether it is safe and can
help slow or prevent the progression of Alzheimer’s, led by Huntington Potter, Ph.D., Professor and
Director of Alzheimer’s disease research, Department of Neurology, Linda Crnic Institute for Down
Syndrome, University of Colorado Anschutz Medical Campus. Leukine is approved for reducing and
preventing infection in people who have received chemotherapy.
• A Phase II clinical trial to determine if the drug Sativex, a cannabis-based liquid medication that was
previously tested for the alleviation of cancer-related pain, reduces brain inflammation and helps slow
the progression to Alzheimer’s disease in people with mild cognitive impairment, led by Isidro Ferrer,
M.D., Ph.D., Coordinator of the group Neuropathology at CIBERNED (Network Center for
Biomedical Research in Neurodegenerative Diseases), Institute of Health Carlos III, Barcelona,
Spain.
• A study to test if treatment with the drug Senicapoc can reduce brain inflammation, alter the rate of
brain amyloid accumulation, and improve memory in people with early Alzheimer’s disease or mild
cognitive impairment. In previous research, a drug similar to Senicapoc helped to reduce brain
inflammation, prevent nerve cell damage, and improve memory in mice with an Alzheimer's-like
condition. The project includes a Phase II clinical trial led by John Olichney, M.D., Professor and
Neurologist at the University of California, Davis. Senicapoc has been shown to be safe in clinical
trials of sickle cell anemia and asthma, but has yet to be tested in people with Alzheimer's.
• A Phase I clinical trial to examine the safety and efficacy to reduce brain inflammation of a novel
therapy manufactured by Longeveron LLC using stem cells derived from healthy adult donors and
that are delivered into the bloodstream of people with mild Alzheimer’s disease. Anthony Oliva,
Ph.D., senior scientist at Longeveron, will serve as principal investigator, and Bernard Baumel, M.D.,
will serve as the clinical investigator of the trial at the University of Miami Miller School of
Medicine. Longeveron is a life sciences company located in Miami, Florida. In past research, this
type of stem cell has demonstrated the ability to target and reduce inflammation, promote tissue
repair, and improve brain function in mouse models of Alzheimer’s disease.